REG - GenIP PLC - Share Placing to raise £350,000 and TVR

GenipAnnouncement

01/05/2026 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260501:nRSA7204Ca&default-theme=true

RNS Number : 7204C  GenIP PLC  01 May 2026

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW
ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH
RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION
(EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE
OF THE EU (WITHDRAWAL) ACT 2018 ("MAR"). IN ADDITION, MARKET SOUNDINGS (AS
DEFINED IN MAR) WERE TAKEN IN RESPECT OF THE PLACING WITH THE RESULT THAT
CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED IN MAR), AS
PERMITTED BY MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT.
THEREFORE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING
ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO THE COMPANY
AND ITS SECURITIES.

1 May 2026

GenIP Plc

("GenIP" or the "Company")

Share Placing to raise £350,000 and TVR

GenIP Plc (AIM:GNIP), a technology consultancy providing AI-driven services to
help research organisations and corporations commercialise their innovations,
is pleased to announce a fundraising of £350,000 (c.US$470,000) (gross)
through a placing of 5,000,000 new ordinary shares of £0.00425 each in the
Company ("Placing Shares") at a price of 7p ("Issue Price") per Placing Share
(the "Placing" or "Fundraising").

 

Key Highlights:

-     £350,000 (US$470,000) before expenses raised pursuant to the
Placing of 5,000,000 Placing Shares at a price of 7p per Placing Share.

 

-     Funds raised will be utilised as follows:

·      £100,000 for staffing, including account management staff to
manage the increasing network of partnerships and alliances.

·      £150,0000 for R&D efforts associated with new product
development and platform development; and

·      £100,000 for general working capital purposes, including
Fundraising fees.

GenIP continues to deliver positive trading, has strengthened its
relationships with academia clients and its recent alliance with Cardinal IP.
The Company recently secured a contract with a university in Peru, which means
that it now operates across 33% of South American nations. It has also signed
a new corporate contract with a healthcare innovation client in Spain
increasing its footprint in Europe and providing access to a network of 122
research groups.

Melissa Cruz, GenIP's CEO, commented:

"This Fundraise comes at a time of significant commercial momentum for GenIP.
The proceeds will enable us to improve the monetization of the increasing
network of partnerships and alliances and continue the programme of product
development. This places the Company in a stronger position for a successful
rest of FY2026."

Placing

The Company has raised £350,000 (before expenses) through the issue of
5,000,000 Placing Shares at an issue price of 7p per Placing Share, which
represents a discount of approximately 38% to the closing mid-price of 11.25p
as at the close of business on 30 April 2026, being the last practicable date
prior to publication of this announcement. The Placing Shares represent
approximately 24.4% of the Company's existing issued share capital. The
Placing was undertaken by CMC Markets UK Plc ("CMC"), trading as CapX, who
acted as the Company's sole placing agent in respect of the Placing.

The net proceeds of the Placing will support GenIP's growth plans, will
strengthen the Company's balance sheet and provide additional working capital.

Appointment of Joint Broker

The Company is also pleased to announce that CMC has been appointed as the
Company's joint corporate broker with immediate effect.

Application for Admission

Application will be made for the Placing Shares to be admitted to trading on
AIM ("Admission"). It is expected that Admission will take place and that
trading will commence on AIM at 8.00 a.m. on or around 8 May 2026. Once
issued, the Placing Shares will rank pari passu with the Company's existing
Ordinary Shares.

Total Voting Rights

Following Admission of the Placing Shares, the enlarged issued share capital
of the Company will comprise 25,517,461 Ordinary Shares. The Company does not
hold any Ordinary Shares in treasury. Consequently, 25,517,461 is the figure
which may be used by shareholders from Admission as the denominator for the
calculation by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the FCA's
Disclosure and Transparency Rules.

Concert Party interest

The Concert Party (as defined in the Admission Document published on 26
September 2024), is currently interested in aggregate in 60.88% of the
existing issued share capital reducing to 48.95% in the enlarged issued share
capital on Admission. Accordingly, following Admission the members of the
Concert Party will hold less than 50 per cent. of the voting rights in the
Company but will continue to hold more than 30 per cent. of the voting rights
of the Company.  If a Concert Party member is in any doubt about the current
position, it should consult the Company and seek their own financial advice
from an appropriately authorised stockbroker, bank manager, solicitor,
accountant or other independent financial adviser who, if taking advice in the
United Kingdom, is duly authorised under the Financial Services and Markets
Act 2000 ("FSMA").

 

ENDS

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                                    Via Redchurch Communications

 Melissa Cruz, CEO

 Beaumont Cornish Limited (Nominated Adviser)                                 Tel:  +44 (0) 20 7628 3396

 Roland Cornish / Asia Szusciak / Andrew Price

 CMC Markets (Joint Broker and Sole Placing Agent)                            th.smith@cmcmarkets.com (mailto:th.smith@cmcmarkets.com)

 Thomas Smith

 AlbR Capital Limited (Joint Broker)                                          Tel: +44 (0)20 7399 9427

 Colin Rowbury                                                                cr@albrcapital.com (mailto:cr@albrcapital.com)

 Jon Belliss                                                                  Jb@albrcapital.com (mailto:Jb@albrcapital.com)

 Redchurch Communications (Financial PR)                                      genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated
Adviser and is authorised and regulated by the FCA. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other persons for providing protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the proposed arrangements described in this announcement or any matter
referred to in it.

Notes to Editors

 

About GenIP

 

GenIP is a next-generation company at the intersection of generative AI and
innovation strategy. We empower corporates, venture funds, and research
institutions to evaluate, commercialise, and scale breakthrough technologies.
By combining proprietary GenAI algorithms with expert human analysis, GenIP
delivers decision-grade insights and talent solutions that accelerate
innovation outcomes.

 

Service Offerings

 

GenIP operates through two synergistic service lines:

 

 

 Service                               Description                                                                   Value Proposition
 Invention Intelligence Product Suite  AI-powered market intelligence reports assessing the commercial potential of  Enables faster, evidence-based decisions on R&D prioritisation,
                                       emerging technologies.                                                        investment, and IP strategy

 Talent and Executive Search Services  Executive search platform using machine learning and NLP to match             De-risks scaling by aligning technical vision with proven executive capability
                                       innovation-driven organisations with commercialisation-ready leadership

 

Together, these services form a unified GenAI-enabled platform for innovation
triage and commercialisation.

 

Vision & Strategy

 

GenIP aims to become the global leader in generative AI analytics for
innovation commercialisation. Our strategy is anchored in three growth
pillars:

 

●     Organic Expansion

Scale Invention Intelligence and Recruitment Services through targeted
outreach to corporates, VCs, and research institutions.

●     Service Deepening

Enhance functionality and margin by expanding GenAI capabilities within both
service lines-unlocking new use cases and customer segments.

●     Strategic Acquisitions

Pursue bolt-on acquisitions of complementary GenAI services with validated
market traction to broaden our offering and accelerate growth.

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEUPUAGAUPQUGG



            Copyright 2019 Regulatory News Service, all rights reserved